Pain And The Use Of Gabapentinoids In German Nursing Home Residents - Results From An Analysis Based On Statutory Health Insurance Data

Background Gabapentinoids (gabapentin and pregabalin) are psychoactive medications that are increasingly used for different conditions. Since there is evidence that psychotropic drugs, in general, are often inappropriately prescribed in elderly patients, we aimed to determine frequency and indications of gabapentinoid prescribing for nursing home residents. Methods We analyzed data from a large German statutory health insurance database. Included were records from people ≥65 years-of-age, who were admitted to a nursing home between January 2010 and December 2014. We determined the number and proportion of common indications for on- and off-label prescriptions, the most frequent co-medications, and the characteristics of patients and prescribers. Results Of 127,277 residents, 9539 (7.5%) received gabapentinoids and 4852 initiated treatment (4.0%; with 66.3% pregabalin). Median age of gabapentinoid initiators was 84 years (78.5% females). In these users, on-label prescribing was found in 57.4%, predominantly for neuropathic pain. Other painful conditions were also chief causes (84.7%) for off-label prescribing. Gabapentinoids were mainly started by general practitioners (64.5%) while pain specialists contributed <2%. Forty-six percent of users received additional opioids and in 27.5% gabapentinoids were prescribed only once. Conclusion Gabapentinoids were frequently used in nursing home residents. Regular co-prescribing with opioids and psychotropic drugs might indicate employment to improve pain or assist treatment of conditions that are frequently associated with disruptive behavior such as dementia. However, more research is needed to better understand decision-making regarding gabapentinoid prescribing, especially in view of aggressive marketing, uncertain analgesic effects, problematic side effects, and uncritical use in the elderly.

[1]  Y. Kuo,et al.  Tricyclic Antidepressant and/or γ‐Aminobutyric Acid–Analog Use Is Associated With Fall Risk in Diabetic Peripheral Neuropathy , 2019, Journal of the American Geriatrics Society.

[2]  B. Bolea-Alamanac,et al.  Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative case report , 2019, British journal of clinical pharmacology.

[3]  S. Pearson,et al.  Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings , 2018, Addiction.

[4]  C. Maher,et al.  Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis , 2018, Canadian Medical Association Journal.

[5]  J. Laporte,et al.  Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database , 2018, Drug Safety.

[6]  C. Bantel,et al.  Practice and bias in intraoperative pain management: results of a cross-sectional patient study and a survey of anesthesiologists , 2018, Journal of pain research.

[7]  H. Laycock,et al.  Between evidence and commerce – the case of sufentanil sublingual tablet systems , 2017, Anaesthesia.

[8]  M. Bennett,et al.  Opioids combined with antidepressants or antiepileptic drugs for cancer pain: Systematic review and meta-analysis , 2018, Palliative medicine.

[9]  U. Bonnet,et al.  How addictive are gabapentin and pregabalin? A systematic review , 2017, European Neuropsychopharmacology.

[10]  F. Howe,et al.  The effect of pregabalin or duloxetine on arthritis pain: a clinical and mechanistic study in people with hand osteoarthritis , 2017, Journal of pain research.

[11]  P. L. Petersen,et al.  Benefit and harm of pregabalin in acute pain treatment: a systematic review with meta-analyses and trial sequential analyses , 2017, British journal of anaesthesia.

[12]  A. Brett,et al.  Gabapentin and Pregabalin for Pain - Is Increased Prescribing a Cause for Concern? , 2017, The New England journal of medicine.

[13]  M. Bhandari,et al.  Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials , 2017, PLoS medicine.

[14]  P. Wiffen,et al.  Gabapentin for chronic neuropathic pain in adults. , 2017, The Cochrane database of systematic reviews.

[15]  A. Birnbaum,et al.  Antiseizure, antidepressant, and antipsychotic medication prescribing in elderly nursing home residents , 2017, Epilepsy & Behavior.

[16]  P. G. Larsson,et al.  Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders—a pharmacoepidemiological study and clinical implications , 2016, European Journal of Clinical Pharmacology.

[17]  E. Calandre,et al.  Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use , 2016, Expert review of neurotherapeutics.

[18]  E. Kharasch,et al.  Wherefore Gabapentinoids?: Was There Rush Too Soon to Judgment? , 2016, Anesthesiology.

[19]  N. Pivac,et al.  Psychotropic medications in older adults: a review. , 2016, Psychiatria Danubina.

[20]  A. Habib,et al.  Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. , 2015, British journal of anaesthesia.

[21]  J B Dahl,et al.  Post‐operative analgesic effects of paracetamol, NSAIDs, glucocorticoids, gabapentinoids and their combinations: a topical review , 2014, Acta anaesthesiologica Scandinavica.

[22]  S. Crystal,et al.  Antipsychotic medication use in nursing homes: a proposed measure of quality , 2014, International journal of geriatric psychiatry.

[23]  R. Rastogi,et al.  Management of chronic pain in elderly, frail patients: finding a suitable, personalized method of control , 2013, Clinical interventions in aging.

[24]  M. Bennett,et al.  Attitudes of health care professionals to opioid prescribing in end-of-life care: a qualitative focus group study. , 2012, Journal of pain and symptom management.

[25]  G. Zaccara,et al.  The adverse event profile of pregabalin: A systematic review and meta‐analysis of randomized controlled trials , 2011, Epilepsia.

[26]  Raymond Miller,et al.  A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin , 2010, Clinical pharmacokinetics.

[27]  A. Kaye,et al.  Pain management in the elderly population: a review. , 2010, The Ochsner journal.

[28]  R. Frank,et al.  The Rise and Fall of Gabapentin for Bipolar Disorder: A Case Study on Off-Label Pharmaceutical Diffusion , 2010, Medical care.

[29]  K. Schmader,et al.  Treatment considerations for elderly and frail patients with neuropathic pain. , 2010, Mayo Clinic proceedings.

[30]  R. Treede,et al.  [Identification and grouping of pain patients according to claims data]. , 2010, Schmerz.

[31]  T. Nurmikko,et al.  Pharmacological treatment of neuropathic pain in older persons , 2008, Clinical interventions in aging.

[32]  G. Sills The mechanisms of action of gabapentin and pregabalin. , 2006, Current opinion in pharmacology.

[33]  Schedules of controlled substances: placement of pregabalin into schedule V. Final rule. , 2005, Federal register.

[34]  R. Kuzniecky,et al.  Comparative Cognitive Effects of Carbamazepine and Gabapentin in Healthy Senior Adults , 2001, Epilepsia.

[35]  H. Hart I: Justice , 1953, Philosophy.